Zitate (Citations)
1 publicationsPublikationen von Forschern, die dieses Produkt verwendenBeschreibung (Description)
Agarotetrol is the chromone derivative from Agarwood, showing very low phosphodiesterase (PDE) 3A inhibitory activity with IC50 value > 100μM[1]. The aqueous extract of agarwood is characterized by a high concentration of Agarotetrol, a bioactive compound demonstrating significant sedative properties. Upon thermal activation, Agarotetrol compound releases benzylacetone, a characteristic aromatic constituent[2]. Agarotetrol serves as a crucial quality control marker for the standardization of agarwood in herbal medicinal preparations[3].
In vitro, Agarotetrol has potential cell protective activity[4]. After 24 hours of incubation with 20μM Agarotetrol, the 150μM corticosterone-induced damage in PC12 cells was significantly alleviated, with a cell viability of 79.50 ± 1.79% [4]. In silico molecular docking and molecular dynamic simulation showed that Agarotetrol had good binding with humanlegumain protein[5].
In vivo, Agarotetrol can cross the blood-brain barrier in vivo with an estimated blood-brain barrier penetration value of 0.8 in SD rats[5]. The combined administration of agarwood essential oil (24.85mg/kg) and agarotetrol-enriched extract powder (7.28mg/kg) (prepared into a cyclodextrin mixture) demonstrated significant pharmacological effects on sleep parameters in p-Chlorophenylalanine-induced insomnia SD rats. Nasal cavity of administration for 7 days resulted in enhanced sleep onset efficiency, reduced sleep latency, and extended total sleep duration [6]. Following a 30-day oral administration regimen of Agarotetrol at a dosage of 6.0g/kg/day, comprehensive biodistribution analysis demonstrated a tissue-specific accumulation pattern in experimental rats, with the highest concentration detected in renal tissue, followed by hepatic, cardiac, and cerebral tissues in decreasing order of magnitude[7].
References:
[1] Sugiyama T, Narukawa Y, Shibata S, et al. Three new 5, 6, 7, 8-tetrahydroxy-5, 6, 7, 8-tetrahydrochromone derivatives enantiomeric to agarotetrol from agarwood[J]. Journal of natural medicines, 2018, 72: 667-674.
[2] Takamatsu S, Ito M. Agarotetrol: a source compound for low molecular weight aromatic compounds from agarwood heating[J]. Journal of natural medicines, 2018, 72: 537-541.
[3] Takamatsu S, Ito M. Agarotetrol as an index for evaluating agarwood in crude drug products[J]. Journal of Natural Medicines, 2022, 76(4): 857-864.
[4] Zhang L, Yi P, Yan H, et al. Five new 2-(2-phenylethyl) chromone derivatives and three new sesquiterpenoids from the heartwood of Aquilaria sinensis, an aromatic medicine in China[J]. Natural Products and Bioprospecting, 2022, 12(1): 2.
[5] Alugoju P, Bhandare V V, Patil V S, et al. In silico molecular docking and molecular dynamic simulation of agarwood compounds with molecular targets of Alzheimer’s disease[J]. F1000Research, 2024, 12: 230.
[6] Lai Y, Hua L, Yang J, et al. The effect of Chinese agarwood essential oil with cyclodextrin inclusion against PCPA-induced insomnia rats[J]. Molecules, 2023, 28(2): 635.
[7] Hou H, Chen T, Xu Z, et al. Study and exploration of the pharmacokinetics of traditional Tibetan medicine Ruyi Zhenbao tablets after single and long-term administration[J]. Frontiers in Pharmacology, 2022, 13: 948693.
Protokoll (Protocol)
| Cell experiment [1]: | |
Cell lines | PC12 cell |
Preparation Method | Undifferentiated PC12 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 100U/mL penicillin, and 100μg/mL streptomycin, maintained at 37°C in a humidified 5% CO2 atmosphere. For experimental treatments, cells were divided into three groups: (1) untreated control (blank, 24h), (2) negative control (150μM, 24h), and (3) positive control (150μM corticosterone plus 20μM Agarotetrol, 24h). Cells were plated in 96-well plates at a density of 1 × 104 cells per well and allowed to adhere for 24 hours prior to compound administration. Following 48 hours of treatment, cell viability was assessed using the MTS assay, with absorbance measurements recorded at 492 nm using a microplate reader. |
Reaction Conditions | 20μM; 24h |
Applications | Agarotetrol has significant protective properties against corticosterone-induced PC12 cell injury. |
| Animal experiment [2]: | |
Animal models | SD rats |
Preparation Method | Sixty-four Sprague-Dawley rats (body weight 180-220g, age 3-4 weeks) were randomly allocated into four experimental groups (n=16 per group) with equal gender distribution (8 males and 8 females): (1) vehicle control, (2) high-dose Agarotetrol (6.0g/kg/day), (3) medium-dose Agarotetrol (3.0g/kg/day), and (4) low-dose Agarotetrol (1.5g/kg/day). Within each group, eight animals were sacrificed at one month post-treatment initiation, and the remaining eight were maintained for an additional two-week withdrawal period prior to sample collection. Serial blood sampling was performed via the retro-orbital plexus at multiple time points: baseline (day 1), mid-treatment (day 15), and treatment completion (day 30). At each sampling day, blood was collected at 0.25, 0.5, 0.75, 1, 2, 4, 8, and 24h post-administration. |
Dosage form | 1.5g/kg/day, 3.0g/kg/day and 6.0g/kg/day for 1, 15 and 30 days; p.o. |
Applications | Agarotetrol has a wide distribution in the rats, after long-term administration, the distribution order of Agarotetrol in various tissues of rats was kidney > liver > heart > brain. |
References: | |
Produktdokumente (Product Documents)
Chemische Eigenschaften (Chemical Properties)
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit
Reviews
Review for Agarotetrol
- 5 Star100%
- 4 Star0%
- 3 Star0%
- 2 Star0%
- 1 Star0%
